52 results about "Percutaneous coronary intervention" patented technology

A noninvasive patient-specific method is provided to aid in the analysis, diagnosis, prediction or treatment of hemodynamics of the cardiovascular system of a patient. Coronary blood flow and pressure can be predicted using a 3-D patient image-based model that is implicitly coupled with a model of at least a portion of the remaining cardiovascular system. The 3-D patient image-based model includes at least a portion of the thoracic aorta and epicardial coronaries of the patient. The shape of one or more velocity profiles at the interface of the models is enforced to control complex flow features of recirculating or retrograde flow thereby minimizing model instabilities and resulting in patient-specific predictions of coronary flow rate and pressure. The invention allows for patient-specific predictions of the effect of different or varying physiological states and hemodynamic benefits of coronary medical interventions, percutaneous coronary interventions and surgical therapies.

A catheter apparatus for percutaneous coronary intervention (PCI) capable of accurately positioning the balloon and stent in a desired position includes an introducer set fixed to an opening of the human artery, a guiding catheter secured to the introducer set and introduced into the artery, a Y-connector coupled with the guiding catheter, a guidewire introduced into the guiding catheter, a balloon catheter introduced into the guiding catheter and having a balloon at the distal end thereof, a minute adjustment portion having a nut and a bolt for minutely adjusting the insertion portion of the balloon catheter in the artery, a combining frame having two legs eachcoupled with the main tube and the nut, respectively, and a clamping portion for holding the balloon catheter firmly in position. The catheter apparatus provided by the present invention helps the physician to place the balloon and stent more accurately in the desired position of the artery so that the PCI operation becomes more accurate, easier and safer.

The invention discloses a prediction device for cardiovascular adverse events of percutaneous coronary intervention based on machine learning. The prediction device is characterized in that a cardiovascular event prediction model is saved in a memory, the cardiovascular event prediction model comprises a trained XGboost model, a LightGBM model, an SVM model, an NN model and corresponding weights of each model. The operating process of the prediction device comprises the steps that to-be-detected clinical characteristic data is received, missing value filling is conducted on the to-be-detectedclinical characteristic data; correlation detection is conducted on the clinical characteristic data on which missing value filling is conducted, and the clinical characteristic value with a crossed relationship is removed; computation is conducted on the clinical characteristic data on which correlation detection is conducted using the trained XGboost model, the LightGBM model, the SVM model andthe NN model to obtain four prediction probabilities, and weighted summation is conducted on the four prediction probabilities to obtain the prediction probability predicted by using the cardiovascular adverse event prediction model.

The subject guide catheter extension system with a micro-catheter delivery catheter includes an outer sheath, an inner member extending within the sheath, and a mechanism for engagement / disengagement of the inner member to / from the sheath. Several mechanisms of engagement / disengagement between the inner and outer members are provided including a friction mechanism, threaded mechanism, pull away sheath, and engagement / disengagement mechanism for pusher's handles. The sheath and the inner member are modified for different engagement / disengagement mechanisms operation. A micro-catheter delivery system provides for an improved atraumatic crossability to the treatment site in an expedited and simplified fashion. During a procedure, a guidewire along with a guide catheter are advanced to the vicinity of the treatment site within a blood vessel. Subsequent thereto, the subject guide catheter extension system is manipulated to advance the micro-catheter along the guidewire inside the guide catheter towards and beyond the site of interest. Once the micro-catheter is in place, the outer sheath slides along the micro-catheter until reaching the lesion, and then the inner member is removed from the sheath, and the sheath then is ready for passing the treatment catheter (stent / balloon) towards the lesion to be treated.

The invention discloses an in-vitro training and testing system for percutaneous coronary interventional surgery. The in-vitro training and testing system comprises an operation platform, a constant-temperature box, a display, a sealed constant-temperature blood collecting box and a heart simulating device, wherein the constant-temperature box simulates the in-vivo environment of a human body, andthe display is connected with the constant-temperature box; the heart simulating device comprises a sealed rigid container, a piston communicated with the rigid container and a heart model arranged in the rigid container; the heart model is connected with an aorta model and a right pulmonary vein simulating pipeline communicated with the blood collecting box; left and right coronary artery modelsare connected to one end of the aorta model, and the far end of each coronary artery model is communicated with the blood collecting box through a silica-gel soft tube; the other end of the aorta model is communicated with one end of an artery simulating tube, the other end of the artery simulating tube is communicated with one end of a femoral artery blood vessel simulating section, and the other end of the femoral artery blood vessel simulating section is communicated with the blood collecting box. The in-vitro training and testing system has the advantages that the interventional surgery scene is restored, the surgery learning time of doctors is shortened, and the operation level of the doctors can be improved.

A system configured to assess the severity of a blockage in a vessel and, in particular, a stenosis in a blood vessel is disclosed. It is further disclosed to provide measurements of a vessel that allow assessment of the vessel and, in particular, any stenosis or lesion of the vessel and simulate diagnostic visualizations using a first visualization device and a second visualization device. Displaying, on a first visualization device, an image of the vessel with treatment diagnostic visualizations based on obtained pressure measurements and displaying, on a second visualization device, a portion of the image of the vessel with diagnostic visualizations based on the obtained pressure measurements is disclosed, wherein the portion of the image of the vessel displayed on the second visualization device is a close up of a region of interest of the vessel.

The invention provides a simulation training system and method supporting personalized percutaneous coronary intervention (PCI). The system includes the functions of personalized cardiac modeling, deformation of heart and blood vessels, motion simulation of interventional guide wires or catheters, virtual X-ray imaging, force haptic feedback and the like, can also simulate common accidents duringsurgery, such as the phenomenon of a guide wire piercing the blood vessels, and can achieve real-time interactive computing efficiency for all the processing processes on one ordinary personal computer. After a patient's data is collected, personalized cardiac modeling can be performed on the patient effectively by a simple interactive operation, then the model is imported into a surgery simulation system, and simulation rehearsal of the surgical process can be performed.

The invention relates to a eukaryotic expression vector carrying human cellular repressor gene of E1A-stimulated gene (hCREG) and a eukaryotic expression vector carrying glycosylation sites mutation hCREG. The invention also relates to preparation of recombinant hCREG protein and glycosylation sites mutation hCREG protein with the eukaryotic expression vector, the actions of the two types of proteins on restricting the proliferation of vascular smooth muscle cells (VSMCs), the preparation of the medicine preventing restenosis after percutaneous coronary intervention (PCI) with the proteins and the applications thereof.

The invention provides a device for detecting conditions of an inner support adhering wall of a coronary artery. The device comprises an image obtaining unit, for obtaining optical coherence tomography images in the coronary artery; a support position calculating unit, for calculating the position of the support in each optical coherence tomography image; an inner wall position calculating unit, for calculating the position of the inner wall of the coronary artery in each optical coherence tomography image; an adhering wall condition determining unit, based on the positions of the support and the inner wall of the coronary artery in each optical coherence tomography image, for determining the conditions of the adhering wall between the support and the inner wall of the coronary artery; and an image outputting unit, according to the conditions of the adhering wall between the support and the inner wall of the coronary artery, for generating and outputting the images for reflecting the conditions of the adhering wall of the inner support of the coronary artery. The device is capable of, based on the intravascular optical coherence tomography (IVOCT) image, rapidly and automatically providing the visual and quantitative conditions of the support adhering wall for the percutaneous coronary intervention.

Devices, systems, and methods for identifying and presenting cardiac treatment options, for assessing the severity of a blockage in a vessel and, in particular, a stenosis in a blood vessel, by obtaining an image of the vessel, obtaining pressure measurements from the vessel, generating a diagnostic visualization image, identifying a treatment option, and generating a predictive visualization image. The various images and options are displayed on a medical personnel display and a patient display.

A catheter apparatus for percutaneous coronary intervention (PCI) capable of accurately positioning the balloon and stent in a desired position includes an introducer set fixed to an opening of the human artery, a guiding catheter secured to the introducer set and introduced into the artery, a Y-connector coupled with the guiding catheter, a guidewire introduced into the guiding catheter, a balloon catheter introduced into the guiding catheter and having a balloon at the distal end thereof, a minute adjustment portion having a nut and a bolt for minutely adjusting the insertion portion of the balloon catheter in the artery, a combining frame having two legs eachcoupled with the main tube and the nut, respectively, and a clamping portion for holding the balloon catheter firmly in position. The catheter apparatus provided by the present invention helps the physician to place the balloon and stent more accurately in the desired position of the artery so that the PCI operation becomes more accurate, easier and safer.

A system and methods are described for improving the management of ischemic cardiac tissue during acute coronary syndromes. The system combines a catheter-based sub-system which allows for simultaneous balloon dilation of a coronary artery and infusion of a carefully controlled perfusate during percutaneous coronary intervention. The system allows for modulation of levels of oxygen at the time of percutaneous intervention. In addition, catheters and systems are provided for administration of fluids with modified oxygen content during an intervention that incorporate upstream flow control members to compartmentalize the perfusion of the target coronary artery and the remainder of the heart.

Devices and methods that mitigate reperfusion injury (RI) in a clinically practical manner so as to avoid significantly increasing time to reperfusion. In general, these systems and methods involve an antegrade approach to deliver a fluid to the myocardium at risk of RI before, during and after reperfusion is established by a percutaneous coronary intervention such as aspiration and stenting.

The invention discloses application of a traditional Chinese medicine composition for preparing drugs for preventing and treating acute myocardial infarction post percutaneous coronary intervention (PCI) no-reflow, wherein the traditional Chinese medicine composition of the invention comprises ginseng, leech, centipede, scorpio, ground beeltle, cicada slough, root of common peony, borneol and the like, and has effects of tonifying qi, invigorating the circulation of blood, eliminating blood stasis and dredging collateral. The clinical study shows that the traditional Chinese medicine composition in the invention can treat and prevent the acute myocardial infarction post PCI no-reflow.

The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method. A method for determining myocardial ischemia comprising subjecting a blood sample which is derived from a test subject and which contains a BNP molecular group containing at least two selected from the group consisting of BNP 1-32 molecule, BNP 3-32 molecule, BNP 4-32 molecule, BNP 5-32 molecule, and a molecule having a mass number larger than that of BNP 5-32 molecule by 16 Da to a detection process capable of distinguishing and quantifying the individual BNP molecules different in mass number to detect the BNP molecular group, wherein myocardial ischemia in the test subject is determined using, as an index, a ratio between a detected intensity of at least one molecule selected from the BNP molecular group and a detected intensity of at least one other molecule selected from the BNP molecular group.

The invention relates to a postoperative tourniquet for percutaneous coronary intervention treatment. The postoperative tourniquet for percutaneous coronary intervention treatment comprises a main fixing plate, wherein a hemostasis module is arranged on the main fixing plate, and fixing adhesive tapes are respectively connected to two sides of the main fixing plate. The hemostasis module comprises a supporting plate and a hemostasis material layer, wherein the supporting plate is arranged on the main fixing plate, the hemostasis material layer is arranged on the supporting plate and comprises two PVA layers and a collagen layer arranged between the PVA layers. The postoperative tourniquet for percutaneous coronary intervention treatment can achieve quick hemostasis, the working amount of mecical workers can be reduced, and a simple hemostasis device can be replaced. The postoperative tourniquet is convenient to use, a hemostasis material is made of an expansible material, can intelligently exert pressure without pressure regulation, misoperation is avoided, and errhysis is decreased to the most degree.

A medical device for anchoring a distal end of a guidewire in a catheter within a coronary artery during a Percutaneous Coronary Intervention including a catheter for being introduced into a coronary artery and a guidewire extending through the catheter. A first anchor device is provided at the proximal end of the guidewire outside of a patient's body and a second anchor is provided at the distal end of the guidewire and catheter to facilitate the movement of interventional devices in the body.

The present disclosure relates generally to the assessment and treatment of vessels, including for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). For example, some embodiments of the present disclosure are suited for identifying the available intervention technique(s) suitable to achieve a desired outcome selected or input by a user. For example, in some implementations a method comprises receiving pressure measurements obtained by one or more intravascular pressure-sensing instruments positioned within a vessel of a patient; receiving an input from a userregarding a desired pressure value for the vessel of the patient; identifying an available treatment option based on the received pressure measurements and the desired pressure value; and outputting,to a display device, a screen display including a visual representation of the available treatment option. Related devices and systems are also described.

The invention is a method for controlled regional reperfusion using ATP-MgCl2 after percutaneous coronary revascularization for acute myocardial infarction, the method comprising the step of administering an effective amount of ATP-MgCl2 to the step of administering an effective amount of ATP-MgCl2 to the infarct-related vessel(s), such as at a dosage level of at least 0.03 mg / kg / min. The method also includes a method for controlled regional reperfusion using ATP-MgCl2 after percutaneous coronary revascularization for acute myocardial infarction, the method comprising the steps of (a) performing cardiac catheterization and coronary angiogram; (b) identifying the infarct-related vessel; (c) performing a left ventriculogram and calculating the left ventricular ejection fraction; and (d) performing a percutaneous coronary intervention; and after percutaneous revascularization of the infarct related vessel, infusing ATP-MgCl2 intracoronary, preferably at a rate of at least 0.03 mg / kg / min through the balloon catheter.

The invention belongs to the field of medical apparatuses and instruments, specifically relates to a medical treatment material for percutaneous coronary intervention, and in particular relates to a guiding catheter with a shapeable inner core. The guiding catheter with the shapeable inner core comprises a hollow catheter body, and the shapeable inner core which is embedded into the catheter body and is coaxially arranged to the catheter body; the inner core comprises a shapeable head end which is arranged at the front end of the inner core in the marching direction, and a pushing rod which is adhered with the shapeable head end; the shapeable head end is equipped with a hollow through cavity through which a guide line passes; a guide line exchange opening is formed in the sidewall of the pushing rod; the shapeable head end is prepared from elastic nitinol material and can be used for in-vivo shaping. With the adoption of the guiding catheter with the shapeable inner core, the problem that the existing general guiding catheter with fixed shaping head end is difficult to reach the pointed coronary opening under the circumstances such as excessively high coronary opening or excessively low coronary opening, which influences the subsequent interventional therapy, can be solved; the shortages that a patient is exposed for an excessively long time due to repeated attempts, and more contrast mediums are used, can be decreased.

The invention provides application of a biomarker to preparation of a kit for predicting restenosis after stent-interventional surgery and a relevant test kit. The biomarker comprises ceramide d18:1 / 18:2, sphingomyelin SM d18:1 / 20:0, sphingomyelin SM d18:1 / 18:2, lecithin PC 18:2 / 20:4, sphingosine 1-phosphate ester and phosphatidylserine PS18:1 / 18:1. As prediction of in-stent restenosis of patientswho suffer from coronary artery diseases after percutaneous coronary intervention (PCI), the biomarker can reduce the probability of occurrence of the in-stent restenosis, and has the advantages of non-invasiveness, high correctness, early stage, high accuracy.

The invention belongs to the field of medicinal preparations and relates to an eptifibatide powder injection, which mainly comprises eptifibatide, carbohydrates and an acidity regulator. The eptifibatide powder injection has the characteristics of high concentration and good stability, can be used for treating acute coronary syndrome including unstable angina pectoris and non-Q wave infarction andcan also be used in percutaneous coronary intervention including angioplasty and atherectomy.

The invention discloses an adjustable bed structure, which comprises a base, a lifting column and a bed board, wherein, one end of the lifting column is provided with a lifting column base, and the other end is provided with a lifting column guard plate; the lifting column base and the base are connected by bolts Fixed connection, the lifting column guard plate and the bed board are fixedly connected by bolts, and the bed board is provided with an upper bed board, a middle bed board and a lower bed board; the connection position of the upper bed board and the middle bed board is provided with an upper body position knob. A lower body position knob is provided at the connecting position of the lower bed board and the middle bed board. One side of the bed board is further provided with a storage table and a horizontal sliding groove, the horizontal sliding groove is provided with a sliding knob, the storage table is provided with a storage table support column and a storage table hinge, and the connection position between the storage table and the storage table support column is provided with Vertical adjustment knob, the lifting height of the lifting column is 30-80cm. The invention has the advantages of simple structure and convenient use, and is suitable for heart coronary angiography and PCI operation at the position of radial artery.

The invention discloses a traditional Chinese medicine composition for preventing restenosis after percutaneous coronary intervention. The traditional Chinese medicine preparation is prepared from the following raw medicines: sapanwood, valerian, Chinese rose, dioscorea nipponica, pummelo flower, sargentg loryvine, motherwort, forsythia, auriculate swallowwort root and longflower stringbush root. The traditional Chinese medicine composition for preventing restenosis after percutaneous coronary intervention, provided by the invention, is capable of reducing the death rate, relieving symptoms, reducing restenosis occurrence, improving the life quality of patients, reducing the treatment cost and ensuring that the patient dependence is good. By adopting a water decoction of the traditional Chinese medicine composition for preventing restenosis after percutaneous coronary intervention, provided by the invention, for treating 40 patients for six months, the restenosis rate of a treatment group is 12.50%, and the restenosis rate of a control group is 32.50%, so that the restenosis rate of the treatment group is obviously lower than the restenosis rate of the control group, wherein P is less than 0.05.

The invention provides a medicine for preventing postoperative restenosis of coronary artery after percutaneous coronary intervention (PCI) and a preparation method, which pertain to the pharmacy field and are characterized in that: the medicine is prepared from the raw materials by decocting with water according to the following weight ratio: 25 to 35 of Chinese rhubarb: 10 to 20 of mirabilite: 10 to 20 of liquorice: 10 to 20 of cinnamon: 10 to 20 of peach kernel: 20 to 30 of leech: 15 to 25 of honeysuckle. The medicine of the invention solves the problems that the postoperative restenosis of coronary artery appearing in percutaneous coronary intervention (PCI) influences the curative effects and the conventional western medicines cause damage to liver function and renal function, massive hemorrhage, etc. when being used for preventing postoperative restenosis of coronary artery.

The invention relates to the use of a urate oxidase, preferably recombinant urate oxidase, for example rasburicase, for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.

The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine composition for treating primary PCI (percutaneous coronary intervention) postoperative poor myocardial perfusion of patients suffering from heart-qi deficiency type ST-segment elevation myocardial infarction. The traditional Chinese medicine composition which is a traditional Chinese medicine comprises, by weight, 4-8 parts of nigella damascena, 4-8 parts of herba alyxiae sinensis, 4-8 parts of Phlegmariurushamiltonii (Spreng.) LoveetLovevar. petiolatus (Clarke) Ching, 4-8 parts of fructus psoraleae, 4-8 parts of semen ginkgo roots, 2-4 parts of meconopsis horridula, 4-8 parts of radix paeoniae alba, 4-8 parts of buddleja asiatica, 4-8 parts of plumbago indica and 4-8 parts of radix glycyrrhizae. The traditional Chinese medicine composition has the advantages that various medicines are used with one another, and accordingly effects of 'nourishing heart-qi and agitating heart vessels' can be jointly realized; myocardial perfusion of the patients suffering from the primary PCI postoperative poor myocardial perfusion and the STEMI (ST-segment elevation myocardial infarction) can be obviously improved.